An innovative clinical trial led by Dr. Nicholas Vitanza, a neuro-oncologist at Seattle Children’s, shows promise that delivering ...

Scientists and clinicians at UCL and Great Ormond Street Hospital (GOSH) studying the effectiveness of CAR T-cell therapies in children ...

Children and young adults who receive CAR T-cell therapy for the most common childhood cancer, acute lymphoblastic leukemia, suffer...

Now, a group of scientists at Children's Hospital Los Angeles have developed a modified version of CAR T that shows promise in targeting...

For some children with the rare eye cancer retinoblastoma, results from a study in mice suggest that a type of immunotherapy known as...

A novel CAR T-cell therapy developed by researchers at UCL and designed to target cancerous tumours, has shown promising early results ...

"A clinical trial will be the only way to truly answer whether this treatment will work in children with resistant disease, but the study...

"The high-ticket price is part of a larger question. 'How much are we willing to pay to survive disease, and how much are governments...

" CAR-T is often called the “most complex drug ever created,” but it is not really a drug in the traditional sense. Unlike an inert...

CAR T-cells are becoming somewhat of a household name, but a new phase I trial is, for the first time, using CAR 'NKT' cells, featuring...